Competitive landscape - pet osteoarthritis medication

Part
01
of one
Part
01

Competitive Landscape - Cosequin, Rimadyl and Previcox

We have entered the requested details about the competitive landscape of Cosequin, Rimadyl, and Previcox on the attached spreadsheet.

  • Cosequin Joint Health Supplement is a nutritional supplement for dogs scientifically researched to sustain healthy joints.
  • Rimadyl was the first NSAID that was approved by FDA for dogs and has been administered more than all other dog's NSAIDs combined.
  • Previcox is produced just for dogs and works fast to relieve pain and inflammation associated with canine OA and make dogs to become active again more easily.
  • Only Cosequin provided pricing for its products on its website. We found pricing for Rimadyl and Previcox on PetMed Express. We have also included other available pricing information.

Research Strategy

To search for the marketing spend of Cosequin, Rimadyl and Previcox, we started by exploring the websites of the manufacturers, Nutramax, Zoetis, and Merial (subsidiary of Boehringer Ingelheim) respectively. We attempted to look for annual reports and other financial information regarding the companies. We hoped to find expenditure information on marketing for the drugs. Only Zoetis and Boehringer Ingelheim are public companies. However, their annual reports and other documents did not provide information on the marketing spend of their respective drugs.

We then searched through dogs/pets websites like Veterinary Advantage Resource, Dogs Naturally Magazine, and Pet Drugs Online. We found general information about marketing of dogs' medicine but there was no specific information on the concerned companies.

We also scoured through other third party sites like PR Newswire, The Balance Careers, Business Wire, Forbes, and Business Insider. We found general information on the pet medication market but there was also no specific information on the concerned companies.

Sources
Sources